Indaptus Therapeutics Past Earnings Performance
Past criteria checks 0/6
Indaptus Therapeutics's earnings have been declining at an average annual rate of -32.2%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
-32.2%
Earnings growth rate
8.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -248.1% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?
Mar 27
Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?
Aug 15Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45
Aug 08Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications
Sep 29Revenue & Expenses Breakdown
How Indaptus Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -15 | 9 | 7 |
| 30 Jun 24 | 0 | -16 | 9 | 8 |
| 31 Mar 24 | 0 | -15 | 9 | 7 |
| 31 Dec 23 | 0 | -15 | 9 | 8 |
| 30 Sep 23 | 0 | -15 | 9 | 7 |
| 30 Jun 23 | 0 | -15 | 9 | 7 |
| 31 Mar 23 | 0 | -15 | 9 | 7 |
| 31 Dec 22 | 0 | -14 | 9 | 6 |
| 30 Sep 22 | 0 | -14 | 9 | 5 |
| 30 Jun 22 | 0 | -14 | 9 | 4 |
| 31 Mar 22 | 0 | -10 | 7 | 3 |
| 31 Dec 21 | 0 | -8 | 5 | 3 |
| 30 Sep 21 | 0 | -5 | 3 | 2 |
| 30 Jun 21 | 0 | -3 | 1 | 3 |
| 31 Mar 21 | 0 | -4 | 1 | 3 |
| 31 Dec 20 | 0 | -4 | 1 | 3 |
Quality Earnings: INDP is currently unprofitable.
Growing Profit Margin: INDP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INDP is unprofitable, and losses have increased over the past 5 years at a rate of 32.2% per year.
Accelerating Growth: Unable to compare INDP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INDP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: INDP has a negative Return on Equity (-248.09%), as it is currently unprofitable.